INTRODUCTION
Connective tissue diseases including Raynaud's phenomenon, systemic sclerosis (SSc), and systemic lupus erythematosus have an autoimmune component that leads to the production of autoantibodies, vascular disease, and remodeling of the vasculature and the connective tissue [1] . The clinical problem can be localized to the hands and feet, or spread to further skin areas and internal organs [1] . SSc particularly when affecting internal organs has the worst prognosis with a decrease in life expectancy [2] .
Genetic predisposition clearly points to the causative role of an aberrant immune response for these diseases. Genetic risk factors for SSc include, for example, specific major histocompatibility complex (MHC) haplotypes [3,4,5 && ,6 ] people may explain clinical endotypes of SSc and also gene by environment interactions. As mentioned above, MHC molecules display peptides to immune cells. Chemical exposures, including exposures to substances from the environment can cause protein modifications, for example, nitration [13, 14] . The nitration modification confers subtle changes to peptides, which in turn are better displayed by certain MHC haplotypes, but not by others [14] . Confirmed 19, 20] indicates that the role of environmental exposures for SSc maybe under-estimated.
The wide scope of the dysfunction of the immune response in SSc renders the treatment of the condition challenging. This is reflected by the breadth of targets of interventions that are currently at the clinical trial stage for SSc. Ongoing clinical trials for SSc are registered worldwide at the clinicaltrials.gov site with the majority being performed in the United States (36) and Europe (43) . Organspecific disease management makes up the largest percentage, followed by trials to identify diagnostics and biomarkers. Patient support (registries, advocacy) and drugs targeting the vasculature and coagulation, cell ablation and cell/tissue transplantation, as well as drugs targeting the immune response/ vaccine/microbial reconstitution make up the majority of the other trials.
PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS
Pulmonary fibrosis, pulmonary hypertension, cardiac disease, and kidney disease as well as early onset Raynaud's phenomenon are predictors of mortality in SSc [2]. The two-year survival rate of SSc-associated pulmonary hypertension is at an estimated 50-60%, despite the availability of treatment for pulmonary hypertension [2, 21, 22] . Mean pulmonary artery pressures that are at the high end of the normal range (21-24 mmHg) are considered borderline pulmonary hypertension [23] . Borderline pulmonary hypertension is considered a risk factor for worsening of the SSc syndrome that may ultimately lead to overt SSc-associated pulmonary hypertension [23] .
IMMUNE RESPONSE INDUCED PULMONARY HYPERTENSION, A VEXING BIOLOGICAL QUESTION
Pulmonary hypertension is characterized by the increase of the pulmonary artery pressure associated with remodeling and constriction of the pulmonary arteries, increased right heart pressure, and remodeling of the right heart [24] . The immune response is thought to play a critical part in the development of SSc-associated pulmonary hypertension [25, 26] . Different immune response subtypes are associated with SSc-associated pulmonary hypertension, including the T helper 2 (Th2) response [25, 27, 28] , Th17 response [25, 29] , and also the Th1-interferon
KEY POINTS
Connective tissue diseases including the sclerosisassociated disease spectrum can have severe clinical consequences particularly when associated with changes in multiple organs, for example, SScassociated pulmonary hypertension.
Under-appreciated gene by environment interactions could be the basis for the breath of dysfunction of the immune system, the vasculature, and the connective tissue in SSc.
These dysregulated responses may have their evolutionary history from response modules used in the communication between the mammalian host and parasitic helminths.
Because the helminth vascular microbiome is missing in a large aspect of the population in westernized countries, the balancing and regulatory cues from helminth parasites are missing thus contributing to the development of the devastating sclerosis spectrum connective tissue diseases.
response [28] . The Th2 and Th17 responses are thought to have organ-independent profibrotic roles by interacting with fibroblasts and thereby contributing to SSc [25] . In support of this notion, the Th2 cytokine, interleukin (IL)-13, has been shown to cause dermal fibrosis in SSC by affecting the skin wherein it is produced by CD8þ lymphocytes [30] . Studies in mice using experimental skin fibrosis models support the profibrotic role of IL-13 [31, 32] .
Experimental studies in mice have shown that a Th2 immune response can cause severe pulmonary arterial remodeling [33,34,35 && ]. Further studies revealed that this response is exacerbated by urban particulate matter (PM2.5) from air pollution [36] . In this case, both pulmonary arterial remodeling and increased right ventricular systolic pressure are induced. Further studies showed that IL-13 and IL-17A are involved in developing the pulmonary hypertension phenotype induced by antigen and particulate matter ( Fig. 1) [37] . Simultaneous blocking of IL-13 and IL-17A significantly reduced right ventricular pressures [37] . Furthermore, we showed that B cells were necessary for the development of increased right ventricular pressures and molecular changes in the right heart in response to sensitization and intranasal challenge with antigen and particulate matter ( Fig. 1) [38 && ]. In this case, the increase in right ventricular systolic pressure and right ventricular molecular changes were restored by reconstituting the B cell deficient mice with antigen specific immunoglobulin G1 [38 && ]. Together, the data show that the immune response is sufficient to induce the pulmonary hypertension phenotype, as schematically shown in Fig. 1 . The questions are: why would the biological response be set up in this particular manner, and why would the immune response that can cause the pulmonary hypertension phenotype be reminiscent of the response that causes the asthma phenotype?
PARASITES-INDUCED PULMONARY HYPERTENSION
Schistosomiasis-associated pulmonary hypertension is driven by the inflammation and host response to parasite antigens. Schistosomiasis is the third most common parasitic disease affecting about 200 to 300 million people in 74 countries including throughout Africa, Brazil, the Middle East, and Southeast Asia [39] . Schistosomiasis is an ancient and chronic disease of humans, mammal, birds, and primates. The first host response to antigens released by these worms is a Th-1 response during acute infection [39] . The host releases tumor necrosis factor (TNF)-a, IL-1, IL-6, IL-12 [40, 41] , transforming growth factor (TGF)-b, and interferon-g [42] [43] [44] . However, during chronic infection, schistosome eggs and egg-derived antigens released by worms migrate to lungs and induce a Th2 response. The Th2 milieu induces tissue-remodeling cytokines such as IL-4 [33, 34, 35 && ], IL-13 [33,35 && ], and resistin-like molecule a (RELMa) [34, 45, 46] . The immune response to the parasite eggs and their antigens together with exacerbated activity of TGF-b induce severe pulmonary arterial remodeling and pulmonary hypertension [35 && ,39,44,47,48] (Fig. 1) . (antigen and PM2.5 [37] ) -are particularly noteworthy. The changes in the lungs and hearts of SSc patients are remarkably similar and cytokine associations have been found that indicate involvements of IL-13 [27, 28] , IL-4 [28] , IL-17A [29] , or interferon [28] . The data schematically represented above were generated using experimental mouse models [33,35 && ,37,79] using cytokine-neutralizing antibodies and gene deficient mice. It is emphasized that the incidence of clinical pulmonary hypertension associated with schistosomiasis infection in humans is still not fully known but is estimated at 6-7% of all infected persons [80] . Two observations are clinically important: first, pulmonary hypertension associated with Schistosomiasis generally fails to improve by only giving antihelminthic treatment [80] , emphasizing the significance of the host (immune) response for developing clinical signs of pulmonary hypertension; second, a majority of Schistosome-infected individuals do not develop pulmonary hypertension, indicating the strength of the cross-adaptation between the human host and the helminth parasite.
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PARASITE-HOST COMMUNICATION

Factors (protein, sugar, cytokines) produced by the parasites
The antigens released by parasites induce host immune response and cause host disease. However, to help shared survival, of host and parasites, the parasites produce several factors (e.g., protein, sugar, cytokines) that can modulate the immune response.
Sugars
Lacto-N-fucopentaose III (LNFPIII) is a sugar found in both parasitic helminths and human milk. Several recent reports showed that LNFPIII from soluble egg antigen also modulate immune response [49] . The protective role of LNFPIII for host is to alleviate hepatosteatosis and insulin resistance [50] . LNFPIII induces alternative macrophage activation and up-regulates the expression of arginase 1 and chitinase-like 3 (Chil3-Ym1) [51] . These alternative macrophage signals protect the host against organ injury through down-regulation of egg-induced inflammation [52] . LNFPIII also induces IL-10, up-regulates T regulatory cells, and inhibits inflammatory responses induced by bacterial lipopolysaccharide [53] .
Growth factor receptor signaling
During intestinal infection with nematode parasites (such as Trichuris muris), the host produces a Th2 immune response for protection against the parasite [54] and induces epidermal growth factor (EGF) family cytokines to proliferate the gut epithelium [55] . For example, EGF-like cytokine amphiregulin (AREG) that is produced as consequence of the Th2 response leads to increased proliferation of the gut epithelium and enhances parasite clearance [56] . Furthermore, AREG enhances the function of T regulatory cells whose function is to restrict the magnitude of the immune response [57] .
Cytokines
The eggs produced by schistosomes during chronic infection cause granulomas and fibrotic disease. Therefore, egg production by the parasite is critical for pathogenesis. TGF-b signaling plays an important role in the embryogenesis of the parasite. The schistosome-genome has several components of the TGF-b pathway including type I receptor, Schistosoma mansoni receptor kinase-1 (SmRK1) [58] , type II receptor (SmRK2) [59] , as well as the signaling molecules downstream of the receptor, the Smad homologs [60] [61] [62] . Furthermore, the mammalian host ligand, TGF-b, can signal in the parasite's TGF-b pathway [63] . Additionally, one report identified the parasite ligand, a parasite-encoded TGF-b superfamily member, Schistosoma mansoni Inhibin/Activin (SmInAct). SmInAct is thought to be critically important for the production of eggs, and this process also involves the immune response by the mammalian host [64] .
Helminth treatment
In western countries and industrialized countries in which the incidence of helminth infection is reduced, there is an increased frequency of immunological diseases including inflammatory bowel disease, asthma, other allergic disease, and autoimmune disease [ ]. The mammalian host had to establish protective mechanisms directed against the parasites. For example, Schistosome cercariae enter via the skin and thickened skin is a better barrier [73] . Furthermore, thickened pulmonary arteries have decreased permeability [74] , a change that would protect from intravascular parasites.
Conversely, by the elimination of parasite infection, the mammalian host lost the communication network with the parasite. As explained above, the host-parasite communication included cues that regulate the homeostasis of many organs including the vasculature, connective tissue and the immune system. The loss of this communication is thought to contribute to the high incidence of immunological diseases [75, 76] . Therefore, a current idea states that helminth infection could protect the host against severe autoinflammatory events while causing parasitism and mild-to-moderate disease [77] . Proof-of-concept studies have explored exposure to helminths for therapy of immune-mediated diseases. For example, helminth treatment reduced the symptoms of inflammatory bowel disease by inducing immune-regulatory networks and mucosal repair and by altering communities of microbiome within the intestinal tract [67 && ,78] .
CONCLUSION
Hypothesis of the missing parasite-host interaction in autoimmunity associated pulmonary hypertension. A tantalizing hypothesis is that cues from the environment, in combination with chronic 
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